接受基于利妥昔单抗化疗的非霍奇金淋巴瘤患者的乙型肝炎再激活：需要教育与关注。
Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention.
作者信息
Yang Ju Dong, Girotra Mohit, Vaid Arjun, Duarte-Rojo Andres
机构信息
Division of Gastroenterology and Hepatology, Department of Medicine, University of Arkansas for Medical Science, Little Rock, AR, USA.
出版信息
J Ark Med Soc. 2013 Nov;110(6):110-2.
Hepatitis B reactivation can occur in patients with inactive chronic hepatitis B receiving rituximab treatment. Therefore, hepatitis B virus (HBV) screening is recommended in patients planned for chemotherapy and antiviral prophylaxis needs to be started prior to initiating the treatment in patients with evidence of HBV infection. We describe a 58-year-old African American man with history of chronic hepatitis B who developed severe (HBV) reactivation while receiving rituximab treatment for Non-Hodgkin's lymphoma (NHL). The report highlights that greater education is needed amongst clinicians regarding risk of HBV reactivation while receiving chemotherapy, particularly with rituximab-based treatment.
接受利妥昔单抗治疗的慢性乙型肝炎非活动期患者可能会发生乙型肝炎再激活。因此，对于计划接受化疗的患者，建议进行乙肝病毒（HBV）筛查，对于有HBV感染证据的患者，需要在开始治疗前启动抗病毒预防。我们描述了一名58岁的非裔美国男性，他有慢性乙型肝炎病史，在接受利妥昔单抗治疗非霍奇金淋巴瘤（NHL）时发生了严重的HBV再激活。该报告强调，临床医生需要更多地了解接受化疗时HBV再激活的风险，尤其是基于利妥昔单抗的治疗。
Zotero 插件